ORIGINAL RESEARCH

Integrated analysis of IncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma

Hongyan Li Xiaonan Zhao Chenghua Li Chuanlun Sheng Zhenzi Bai

Infectious Department, China-Japan Union Hospital, Jilin University, Changchun 130033, China

Correspondence: Zhenzi Bai Infectious Department, China-Japan Union Hospital, Jilin University, No.126 Xiantai Street, Changchun 130033, China Tel +86 431 8499 5690 Email zzb20905@163.com



Background: There is evidence that abnormal expression of lncRNAs is associated with hepatitis B virus (HBV) infection-induced hepatocellular carcinoma (HCC). However, the mechanisms remain not fully elucidated. The study aimed to identify novel lncRNAs and explore their underlying mechanisms based on the ceRNA hypothesis.

Methods: The RNA and miRNA expression profiling in 20 tumor and matched adjacent tissues from HBV–HCC patients were retrieved from the Gene Expression Omnibus database under accession numbers GSE77509 and GSE76903, respectively. Differentially expressed lncRNAs (DELs), miRNAs (DEMs), and genes (DEGs) were identified using the EdgeR package. Protein–protein interaction (PPI) network was constructed for DEGs followed by module analysis. The ceRNA network was constructed based on interaction relationships between miRNAs and mRNAs/lncRNAs. The functions of DEGs were predicted using DAVID and BinGO databases. The prognosis values (overall survival [OS] and recurrence-free survival [RFS]) of ceRNA network genes were determined using The Cancer Genome Atlas (TCGA) data with Cox regression analysis and Kaplan–Meier method.

Results: The present study screened 643 DELs, 83 DEMs, and 1,187 DEGs. PPI network analysis demonstrated that CDK1 and CCNE1 were hub genes and extracted in functionally related modules. E2F2, CDK1, and CCNE1 were significantly enriched into cell cycle pathway. FAM182B-miR-125b-5p-E2F2 and LINC00346-miR-10a-5p-CDK1/CCNE1 ceRNA axes were obtained by constructing the ceRNA network. Patients with high expressions of DELs and DEGs in the above ceRNA axes had poor OS, while patients with the high expression of DEMs possessed excellent OS. CDK1 was also an RFS-related biomarker, with its high expression predicting poor RFS. The upregulation of LINC00346 and CDK1 but the downregulation of miR-10a-5p in HCC was validated in other microarray datasets and TCGA database.

Conclusion: The LINC00346-miR-10a-5p-CDK1 axis may be an important mechanism for HBV-related HCC, and genes in this ceRNA axis may be potential prognostic biomarkers and therapeutic targets.

Keywords: hepatocellular carcinoma, hepatitis B virus, ceRNA, lncRNA, miRNA, prognosis, bioinformatics analysis, TCGA

Introduction

Hepatocellular carcinoma (HCC) is the fourth most prevalent human malignancy and the third cause of cancer-related deaths in China.¹ In 2015, it is estimated that there are 466,100 new cases and 422,100 deaths due to this disease.¹ Although patients with HCC can be managed with a series of therapeutic methods (including surgical resection,

Cancer Management and Research 2019:11 877-897

Construction of the set of the se

adjuvant chemotherapy, radiotherapy, and liver transplantation), the overall 5-year survival rate still remains poor (less than 20%).² Epidemiological studies have shown that chronic hepatitis B virus (HBV) infection is the predominant risk factor for the development, metastasis, and recurrence of HCC, accounting for about 80% of all HCC in China.³⁻⁵ Thus, it is necessary to further investigate the molecular mechanisms of HBV-related HCC in order to screen novel prognostic biomarkers and develop effective therapeutic strategies.

Recently, there have studies to indicate that the abnormal expression of lncRNAs, a class of noncoding RNAs longer than 200 nt in length, is associated with the development of various cancers, including HBV-related HCC.6,7 For example, Zuo et al found that lncRNA AX800134 was upregulated in HBV-positive HCC compared with HBV-negative HCC. Silencing AX800134 with siRNA interference significantly suppressed the growth and invasion but enhanced spontaneous apoptosis of HBx-expressing HepG2 cells.8 The study of Lv et al revealed that the expression of lncRNA DREH was frequently downregulated in HBV-associated HCC tissues in comparison with adjacent noncancerous hepatic tissues. Inhibition of DREH expression by HBx remarkably promoted the proliferation of HCC cells in vitro and in vivo.9 Yang et al identified that lncRNA-HEIH was highly expressed in liver samples from patients with HBV-related HCC. The expression level of lncRNA-HEIH in HBV-related HCC was significantly associated with recurrence and was an independent prognostic factor for survival.¹⁰ However, the mechanisms of IncRNAs in HBV-related HCC remain not fully elucidated.

Previously, emerging evidence has demonstrated that IncRNAs may function as molecular sponges for a miRNA through their miRNAs response elements (MREs) and thereby influence the translation inhibition or mRNA degradation of the transcript on the targets by the respective miRNAs, which is proposed as ceRNA hypothesis.11 Accumulating data also indicated that this regulatory action plays important roles in HCC development.^{12,13} For example, Lv et al14 showed that lnRNA Unigene56159 promoted the migration and invasion of HCC cells by acting as a ceRNA for miR-140-5p to de-repress the expression of Slug and induce the epithelial-mesenchymal transition (EMT). Mo et al¹⁵ observed the upregulated LINC01287 competitively bound to miR-298 and increased the expression of its target gene STAT3 to promote EMT and invasion of HCC cells. lncRNA n335586 was also reported to promote EMT of HCC cells and then migration as well as invasion through facilitating the expression of its host gene creatine kinase, mitochondrial 1A (CKMT1A) by competitively binding miR-924.¹⁶ IncRNA SNHG12 functioned as an oncogene to accelerate tumorigenesis and metastasis of HCC cells by sponging miR-199a/b-5p, which resulted in the high expression of *MLK3* (mitogen-activated protein kinase kinase kinase 11) and activated the NF-κB pathway.¹⁷ HCAL directly interacted with and functioned as a sponge for miR-15a, miR-196a, and miR-196b to modulate lysosomal protein transmembrane 4 beta (*LAPTM4B*) expression in HCC.¹⁸ However, studies performed to investigate the ceRNA mechanisms of lncRNAs for HBV-related HCC were rare.^{14,16}

The goal of this study was to identify novel lncRNA– miRNA–mRNA interaction axes for explaining the development of HBV-associated HCC by constructing a ceRNA regulatory network using sequencing data collected from a public database. Also, the prognosis performance of related lncRNAs, miRNA, and mRNAs was also validated by utilizing The Cancer Genome Atlas (TCGA) datasets. We believe that our study may provide novel prognostic biomarkers and therapeutic targets for HBV-associated HCC.

Methods

Data collection and preprocessing

Two datasets under accession numbers GSE77509¹⁹ and GSE76903¹⁹ were retrieved from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). These two datasets examined the RNA expression profiling and noncoding (miRNA) expression profiling in 20 primary tumors and 20 matched adjacent normal tissues from patients with HBV-induced HCC by high-throughput sequencing via HiSeq 2500 System (Illumina, San Diego, CA, USA). The samples were the same for the two datasets. The fragment per kilobase per million mapped reads (FPKM) expression data in TXT files were downloaded and preprocessed by removing low abundance genes with an FPKM of <1. The lncRNA and mRNA genes in RNA expression profiling were annotated based on the Ensembl Gene ID and HUGO Gene Nomenclature Committee (HGNC; http://www.genenames.org/).²⁰

Differentially expressed RNA analysis

The differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs), and differentially expressed miRNAs (DEMs) between primary tumors and adjacent normal tissues were identified using the EdgeR package of R software (Version 3.22.3; http://www.bioconductor.org/pack-ages/release/bioc/html/edgeR.html).²¹ *P*-value was adjusted to false discovery rate (FDR) with multitest package (Version 2.36.0; http://bioconductor.org/packages/release/bioc/html/ multtest.html).²² The FDR of <0.05 and |logFC(fold change)| >1 were set as the statistical threshold value. Hierarchical cluster heatmap representing the expression intensity and direction of DEGs, DELs, and DEMs was generated using the pheatmap R package (Version: 1.0.8; <u>https://cran.r-project.org/web/packages/pheatmap</u>) based on Euclidean distance.

Protein–protein interaction (PPI) network

The Search Tool for the Retrieval of Interacting Genes/ Proteins (STRING; Version 10.0; <u>http://stringdb.org/</u>) database23 was used to assess the direct and indirect correlations between DEGs. The screened interaction pairs among DEGs were used to construct the PPI network with the Cytoscape software (Version 3.6.1; www.cytoscape.org/).²⁴ The topological features of the PPI network, consisting of degree (the number of edges [interactions] of a node protein]), betweenness centrality (BC; the number of shortest paths that run through a node), closeness centrality (CC; the average length of the shortest paths to access all other proteins in the network), and average path length (APL; the average of distances between all pairs of nodes), were then calculated using the CytoNCA plugin in cytoscape software (http://apps.cytoscape.org/apps/cytonca)25 to determine which genes were hub nodes. Functionally related clusters with well-interconnected genes were further identified from the PPI network using the Molecular Complex Detection (MCODE; Version: 1.4.2, http://apps.cytoscape.org/apps/ mcode) algorithm²⁶ with default scoring options. Modules with score >4 and node >6 were considered to be significant.

Function enrichment analysis

Gene Ontology (GO) Biological Process term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs were conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (Version 6.8; <u>http://david.abcc.ncifcrf.</u> <u>gov</u>)²⁷ and BinGO²⁸ plugin in Cytoscape to predict their underlying functions. Statistical significance was defined as FDR <0.05.

IncRNA-miRNA-mRNA ceRNA regulatory network construction

The miRcode database (Version 11; <u>http://www.mircode.</u> org/)²⁹ was used to screen the interaction relationships between DELs and DEMs, and then, the DELs–DEMs interaction network was constructed using the Cytoscape software (Version 3.6.1; <u>www.cytoscape.org/</u>).²⁴ The target genes of DEMs in the DELs–DEMs interaction network were predicted using the miRwalk database (Version 2.0; <u>http://www.zmf.umm.</u> <u>uni-heidelberg.de/apps/zmf/mirwalk2</u>),³⁰ which were then overlapped with the DEGs to obtain the DELs–DEMs–DEGs regulatory relationships. The negative interaction pairs between DEMs and DEGs/DELs were integrated to construct the DELs–DEMs–DEGs ceRNA network using the Cytoscape software (Version 3.6.1; <u>www.cytoscape.org/</u>).²⁴

Furthermore, all known HCC-related pathways were downloaded from Comparative Toxicogenomics Database (CTD; <u>http://ctd.mdibl.org/</u>),³¹ which was then overlapped with the pathways enriched by the genes in the ceRNA network to obtain potentially HCC-related ceRNA network.

Prognosis values of DELs, DEMs, and DEGs in ceRNA network

The miRNAs and mRNAs expression profile data of HCC were also collected from TCGA (https://gdc-portal.nci.nih.gov/) database, with only the HBV samples having survival information, included. Univariate Cox regression analysis was performed to screen prognosis-related DELs, DEMs, and DEGs using the survival package (Version 2.40.1; https://cran.r-project.org/package=survival). The samples were then classified into a low-expression group (< median) and a high-expression group (> median) based on the expression of each prognosis-related DEL, DEM, and DEG. The Kaplan–Meier (KM) method with the log-rank test was employed to compare the overall survival (OS) and recurrence-free survival (RFS) between the high- and low-expression groups through the GraphPad Prism software (Version 5; GraphPad Software, Inc., La Jolla, CA, USA). *P*<0.05 was considered to be statistically significant.

Validation of expressions of crucial DELs, DEMs, and DEGs in ceRNA network

The expressions of crucial DELs, DEMs, and DEGs were also validated in TCGA dataset and other microarray datasets that detected the mRNA (GSE121248: 70 vs 37; GSE94660³²: 21 vs 21; GSE25599³³: 10 vs 21 normal), miRNA (GSE69580: 5 vs 5), and lncRNA (GSE27462³⁴: 5 vs 5) expression profile between tumor and matched adjacent tissues from HBV–HCC patients. All microarray datasets were also collected from the GEO database. The expression difference was tested by *t*-test. *P*<0.05 was set as statistical significance.

Results Differential expression analysis

A total of 133 lncRNAs, 18,628 protein-coding mRNAs, and 2,578 miRNAs were annotated in mRNA-seq and miRNA-seq data. After removing the low abundance genes with an

FPKM of <1, 80 lncRNAs, 16,169 protein-coding mRNAs, and 874 miRNAs were left for differential expression analysis. Based on the given threshold (FDR <0.05 and |logFC|>1), a total of 43 DELs (14 downregulated and 29 upregulated), 83 DEMs (10 downregulated and 73 upregulated), and 1,187 DEGs (650 downregulated and 537 upregulated) were identified between adjacent normal tissues and primary tumors (Table 1). The heat map analysis showed that the samples with similar features tended to be clustered according to the expressions of DELs (Figure 1A), DEMs (Figure 1B), and DEGs (Figure 1C).

Function enrichment for DEGs

The upregulated and downregulated DEGs were subjected to the DAVID to predict their functions. The results indicated that 16 GO biological process terms were obtained for the upregulated genes, mainly involving cell cycle (ie, *E2F2*, *CDK1*, *CCNE1*, *BUB1*, *UBE2C*, and *CCNB1*), while 27 GO biological process terms were enriched for the downregulated genes, mainly involving inflammatory response (*PF4* and *CXCR1*) (Table 2 and Figure 2A). Furthermore, the KEGG pathway enrichment analysis was performed. In line with the GO enrichment results, the cell cycle (*E2F2*, *CDK1*, *CCNE1*, *BUB1*, and *CCNB1*) and p53 signaling pathway (*CDK1*, *CCNE1*, and *CCNB1*) were also obtained for the upregulated genes, while cytokine–cytokine receptor interaction was enriched for the downregulated genes (*PF4* and *CXCR1*) (Table 3 and Figure 2B).

PPI network construction

Using the STRING database, 2,065 interaction relationship pairs (eg, BUB1–CDK1) were obtained between the 357 DEGs (182 downregulated and 175 upregulated), which were used for constructing a PPI network (Figure 3). After calculating the topological features for each protein in PPI network, CCNB1, CDK1, G protein subunit gamma 4 (GNG4), UBE2C, G protein subunit gamma transducin 1 (GNG71), kinesin family member 4A (KIF4A), PF4, and G protein subunit gamma 13 (GNG13) were found to be shared in four topological characteristics and ranked in the top 30, suggesting that they may be hub genes (Table 4).

Four significant functionally related modules (Figure 4) were subsequently screened using the MCODE, among which the module 1 was the most significant with score =14.474 and node =38, followed by module 2 with score =13.152 and node =46. Also, GO analysis of genes in modules 1 and 2 with BinGO plugin of Cytoscape indicated that they were involved in mitotic cell cycle (*CCNB1, CDK1, BUB1,* and *UBE2C*) and cell surface receptor-linked signaling pathway (*PF4* and *CXCR1*) (Table 5).

Table I Differentially expressed genes, miRNAs, and IncRNAs

	1 .			r				500
Symbol	LogFC	FDR	Symbol	LogFC	FDR	Symbol	LogFC	FDR
CDC6	1.05	2.01E-03	hsa-miR-215-3p	29.41	3.08E06	LINC01662	4.62	1.21E-07
CCNEI	1.02	1.22E-02	hsa-miR-301b	3.80	8.46E–11	DSCR8	4.49	1.73E–17
CDKI	1.04	2.02E-03	hsa-miR-483-3p	3.42	3.40E-09	LINC01976	4.30	7.43E-06
E2F2	1.03	7.83E-03	hsa-miR-410-3p	3.25	1.76E-08	LINC00632	3.70	8.51E-13
BUBI	1.11	6.22E-04	hsa-miR-7974	3.25	3.05E08	DSCR4	3.63	2.03E-12
CCNBI	1.03	2.17E-03	hsa-miR-483-5p	3.22	2.62E-08	LINC02089	3.50	9.85E-05
SFN	1.54	4.46E-06	hsa-miR-200c-3p	3.17	4.31E08	MIR2052HG	3.34	4.32E-11
GNG4	1.48	6.54E-05	hsa-miR-183-5p	3.11	6.10E-08	PRNT	2.54	1.17E-03
UBE2C	1.23	2.15E-04	hsa-miR-1910-5p	3.09	4.44E-04	LINC00346	2.02	3.33E05
GNGTI	2.04	1.49E-05	hsa-miR-493-5p	3.08	8.66E08	FAM182B	1.30	1.04E-02
KIF4A	1.15	5.96E-04	hsa-miR-139-5p	-2.22	1.49E-04	PACRG-AS3	-1.24	2.72E-02
GNG13	1.40	1.87E-02	hsa-miR-30c-2-3p	-1.59	1.04E-02	LINC01558	-1.59	1.17E-03
PF4	-1.36	2.03E-02	hsa-miR-378i	-1.54	1.32E-02	LINC02312	-1.60	1.47E-03
IL-6	-1.04	2.94E-02	hsa-miR-199a-5p	-1.45	2.11E-02	LINC02453	-1.74	3.36E-04
CXCRI	-1.056	1.64E-02	hsa-miR-30a-5p	-1.45	2.16E-02	LILRB I -AS I	-1.87	0.013104
INS	-3.6	9.75E–11	hsa-miR-125b-5p	-1.43	2.29E-02	LINCO1561	-2.05	7.28E-05
RD3L	-3.16	2.70E-10	hsa-miR-378d	-1.43	2.43E-02	LINC01550	-2.09	1.89E-05
VGLLI	-2.96	4.88E-06	hsa-miR-10a-5p	-1.41	2.62E-02	LINC01620	-2.16	2.77E-05
тн	-2.85	7.02E-15	hsa-miR-133a-3p	-1.38	3.15E-02	LINC01554	-2.19	5.61E-06
CLDN8	-2.83	3.13E-06	hsa-miR-101-3p	-1.37	3.12E-02	B3GALT5-AS1	-2.31	3.83E06

Abbreviations: FC, fold change; FDR, false discovery rate.




Figure I Hierarchical clustering and heat map analysis of differentially expressed lncRNAs (**A**), miRNAs (**B**), and genes (**C**). Notes: Each row represents a sample, and each column represents an lncRNA, miRNA, or gene. High- or low-relative expression is displayed as a red or blue strip, respectively. Each group contained 20 different samples. Abbreviations: T, tumor; N, normal.

CeRNA network construction

By searching the miRcode database, 14 DELs–DEMs interaction relationship pairs (including five DELs, all upregulated, and 10 DEMs, five upregulated and five downregulated) were predicted, which were used for constructing the DELs–DEMs network. Subsequently, the target genes of these 10 DEMs were predicted with the miRwalk database. After removal of the positive–negative relationships between DEMs and DEGs, 113 DELs–DEMs interaction relationship pairs (including eight DEMs, three upregulated and five downregulated, and 82 DEGs, 67 upregulated and 15 downregulated) were left for constructing the DEMs–DEGs network. By integrating the DELs–DEMs network and DEMs–DEGs network, a DELs–DEMs–DEGs ceRNA network was established containing 95 nodes (five DELs, eight DEMs, and 82 DEGs) and 239 edges (14 DELs–DEMs, 113 DELs–DEGs, and 112 DEGs–DEGs) (Figure 5).

Function enrichment analysis with DAVID showed the genes in the ceRNA network participated in four significant KEGG pathways, including cell cycle, p53 signaling pathway, neuroactive ligand-receptor interaction, and pathways in cancer (Table 6). By searching the CTD database with "Hepatocellular Carcinoma" as the keyword, 244 KEGG pathways were found to be associated with HCC. Among them, three were common with the enrichment results of the genes in the ceRNA network, including cell cycle (*CCNE1*, *E2F2*, and *CDK1*), p53 signaling pathway (*CCNE1* and *CDK1*), and pathways in cancer (*E2F2*). Thus, the DELs–DEMs–DEGs interaction relationship pairs associated with these three pathways were extracted to form the HCC-related ceRNA network

Category	Term	FDR	Genes
Up	GO:0007049~cell cycle	4.24E–10	E2F1, KIF23, E2F2, KIFC1, XRCC2, E2F7, E2F8, MAEL, PKMYT1, TTK, PTTG1, AURKB, GTSE1, KIF2C, CCNE1, CDCA8, CDC45, CDCA2, PIWIL3, CDCA5, CDC6, CDK1, EGFL6, MND1, PBK, HMGA2, UBE2C, PRDM9, BUB1B, ERN2, NEK2, ANLN, CEP55, SPC24, SPC25, NCAPH, DUSP13, HJURP, NCAPG, CENPA, BUB1, FBXO43, SKA3, SKA1, TRIP13, EXO1, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, CDKN3, CDC25C, CDC25A, GSG2, CCNB1, CCNB2, TEX11
	GO:0022402-cell cycle process	1.13E-11	KIF23, E2F1, KIFC1, XRCC2, MAEL, PKMYT1, TTK, AURKB, PTTG1, GTSE1, CCNE1, KIF2C, CDCA8, CDCA2, PIWIL3, CDCA5, CDC6, CDK1, MND1, PBK, UBE2C, HMGA2, PRDM9, BUB1B, ERN2, NEK2, ANLN, CEP55, SPC24, SPC25, NCAPH, DUSP13, CENPA, NCAPG, FBXO43, BUB1, SKA3, SKA1, TRIP13, EXO1, DLGAP5, KIF18A, NUF2, NDC80, BIRC5, CDC20, CDC25C, CDKN3, CDC25A, CCNB1, CCNB2, TEX11
	GO:0022403~cell cycle phase	I.74E–15	ECCNB2, TEXTT E2F1, KIF23, KIFC1, XRCC2, NEK2, MAEL, TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, GTSE1, SPC24, CCNE1, KIF2C, SPC25, NCAPH, CDCA8, DUSP13, NCAPG, BUB1, FBXO43, CDCA2, SKA3, PIWIL3, SKA1, CDCA5, TRIP13, EXO1, CDK1, CDC6, DLGAP5, NUF2, KIF18A, MND1, CDC20, BIRC5, NDC80, PBK, HMGA2, CDKN3, CDC25C, UBE2C, CDC25A, CCNB1, PRDM9, CCNB2, BUB1B, TEX11
	GO:0000279M phase	3.28E-16	KIF23, KIFC1, XRCC2, NEK2, MAEL,TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, SPC24, KIF2C, SPC25, NCAPH, CDCA8, DUSP13, NCAPG, BUB1, FBXO43, CDCA2, SKA3, PIWIL3, SKA1, CDCA5, TRIP13, EXO1, CDK1, CDC6, DLGAP5, NUF2, KIF18A, MND1, CDC20, BIRC5, NDC80, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, PRDM9, CCNB2, BUB1B, TEX11
	GO:0000278~mitotic cell cycle	2.13E-11	E2F1, KIF23, KIFC1, NEK2, TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, GTSE1, SPC24, CCNE1, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, CENPA, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, CDC20, BIRC5, NDC80, PBK, HMGA2, CDKN3, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B
	GO:0007067~mitosis	6.55E–14	KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B

Table 2 GO enrichment for differentially expressed genes using the DAVID database

(Continued)

Table 2 (Continued)

Category	Term	FDR	Genes
	GO:0000280~nuclear division	6.55E-14	KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB,
			PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH,
			NCAPG, BUB I, CDCA2, SKA3, SKA I, CDCA5, CDK I,
			CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80,
			CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A,
			CCNB1, CCNB2, BUB1B
	GO:0000087~M phase of mitotic cell cycle	9.83E-14	KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55,
			AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8,
			NCAPH, NCAPG, BUBI, CDCA2, SKA3, SKA1,
			CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A,
			BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C,
			UBE2C, CDC25A, CCNBI, CCNB2, BUBIB
	GO:0048285~organelle fission	1.97E-13	KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55,
			AURKB, PTTGI, SPC24, KIF2C, SPC25, CDCA8,
			NCAPH, NCAPG, BUBI, CDCA2, SKA3, SKA1,
			CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A,
			BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C,
			UBE2C, CDC25A, CCNB1, CCNB2, BUB1B
	GO:0051301~cell division	2.47E-08	KIF23, KIFC1, NEK2, ANLN, CEP55, AURKB, PTTG1,
		2.02.00	SPC24, CCNE1, SPC25, CDCA8, NCAPH, NCAPG,
			CDCA2, BUB1, SKA3, POU3F2, SKA1, CDCA5,
			CDK1, CDC6, NUF2, BIRC5, NDC80, CDC20,
			HMGA2, UBE2C, CDC25C, CDC25A, CCNB1,
			CCNB2, BUB1B
Down	GO:0007267~cell–cell signaling	1.82E-07	EDN3, GABRB3, FCRL2, VIPR1, VIPR2, GDNF,
Down	GO.0007207~cen–cen signaling	1.021-07	WNT2, KCNQ5, WISP2, SLCIA2, GRIN2B,
			CHRNA4, EFNB3, NPBWR1, IL26, NRXN1, NTSR1,
			IL22, SIGLEC6, GRM7, WNT9A, DRD I, GRAP,
			OXT, DRD5, TH, MME, RIMS1, CCL24, INS,
			CCL21, PRIMA1, BMP3, IL6, PLP1, NOS1, NTF3,
			DLGAP2, GABRA5, NPY5R, KCNK3, CCL17, WNT7B,
			CXCL14, PNOC, GRIAI, NTRK2, ADRAIA, SLC5A7,
	CO 000(052 + (2.83E-07	WNT7A, IL2, HTR2A KLRC4, KLRC2, KLRC3, CXCR1, CFP, GRIN2B,
	GO:0006952~defense response	2.03E-07	HAMP, RNASE7, IFNG, XCR1, NLRP7, CAMP,
			PRG2, PSG3, IL22, NCR1, NCR3, CCR9, PROK2,
			PSG8, PPBP, CD40LG, GRM7, DEFA3, PLA2G2D,
			CTSG, NGF, KIR3DL2, CLEC1B, C7, DRD1, CCK, CCL24, AZU1, FCN3, INS, CCL21, FCN2, CNR2,
			SFTPD, ILI RAPL2, SELP, IL6, IL5, ILI RL1, GABRA5,
			CCL19, CD5L, STAB2, S100A12, CCL17, MPO,
	CO-0044057 mm h // /	2 475 05	SELE
	GO:0044057~regulation of system process	3.67E–05	BMP10, EDN3, DRD1, CCK, ERBB4, MYL3, EDN2,
			DRD5, OXT, TH, GDNF, DES, GRIN2B, INS, IFNG,
			LGII, ARC, GNAOI, NOSI, NTF3, NPYIR, NPY5R,
			PROK2, TNNT3, CHRM2, NTRK2, TBXA2R,
			AVPRIA, IL2, HTR2A, NGF
	GO:0007268~synaptic transmission	1.17E–04	DRD I, GABRB3, DRD5, OXT, TH, VIPRI, RIMSI,
			WNT2, KCNQ5, SLC1A2, GRIN2B, CHRNA4,
			PRIMA I, PLP I, NOS I, NTF3, DLGAP2, NPBWR I,
			GABRA5, NRXN1, NTSR1, NPY5R, KCNK3, PNOC,
			GRIA I, GRM7, SLC5A7, WNT7A, HTR2A

(Continued)

 Table 2 (Continued)

Category	Term	FDR	Genes
	GO:0051046~regulation of secretion	1.79E-03	EDN3, IL6, EDN2, OXT, FGF23, NPY I R, GDNF,
	_		NPY5R, GCK, GRIN2B, CD40LG, INS, GRM7, IFNG,
			NTRK2, AVPR1A, CHRNA4, TRPV6, IL2, HTR2A,
			NGF
	GO:0006935~chemotaxis	3.12E-03	EDN3, IL6, EDN2, CXCR1, CCL19, PF4, CCL17,
			CCR9, AZU1, CCL24, PROK2, PPBP, CXCL14,
			CCL21, IFNG, SFTPD, XCR1, LECT2
	GO:0042742~defense response to bacterium	8.64E-03	SELP, IL6, CAMP, PRG2, STAB2, S100A12, AZU1,
			CFP, PPBP, HAMP, RNASE7, IFNG, DEFA3, CTSG
	GO:0050900~leukocyte migration	9.20E-03	AZUI, EDN3, SELP, IL6, EDN2, IFNG, ELANE,
			SFTPD, PF4, SELE
	GO:0022610~biological adhesion	I.39E-02	CLDN8, CLSTN2, OPCML, DSCAMLI, CLDN10,
			LICAM, MEGFIO, WISP2, SRPX, TNR, DPT,
			DSCAM, TECTA, SELP, MAG, HAPLN4, RET, CDHR1,
			PCDH11X, CDHR2, IGFALS, SIGLEC11, AJAP1,
			STAB2, NRXN1, PCDH19, CTNNA3, CLEC4M,
			DSG4, LYVE1, FREM3, HEPACAM, SIGLEC6, FREM2,
			CD40LG, DSG1, CDH19, ITGAD, CNTN3, SELE,
			COL20A1, IL2
	GO:0006954~inflammatory response	2.80E-02	SELP, C7, IL6, IL5, CXCR1, CCL19, IL22, S100A12,
			CCL17, NCR3, AZU1, CFP, CCL24, PROK2, FCN3,
			CD40LG, INS, CCL21, FCN2, CNR2, XCR1, SELE,
			PLA2G2D, NGF

Note: Top 10 terms were listed.

Abbreviations: DAVID, Database for Annotation, Visualization and Integrated Discovery; FDR, false discovery rate; GO, Gene Ontology.

(Figure 6), in which four DELs (DSCR4, FAM182B, PRNT, and LINC00346), five DEMs (hsa-miR-199a-5p, hsa-miR-30a-5p, hsa-miR-125b-5, hsa-miR-10a-5p, and hsa-miR-133a-3p), and seven DEGs (*CDC6, CCNE1, CDK1, E2F2, BUB1, CCNB1,* and *SFN*) were involved.

Prognosis prediction for DELs, DEMs, and DEGs

Ninety-eight HBV-related HCC samples, which have been used for mRNA and miRNA sequencing, were collected from TCGA database. Univariate Cox regression analysis was then used to screen OS- and RFS-related DELs, DEMs, and DEGs from HCC-related ceRNA network in these samples. The results showed that two DELs, four DEMs, and seven DEGs were significantly associated with OS, but only five DEGs were significantly associated with RFS (Table 7). KM curve was subsequently drawn according the expression level of each DEL, DEM, and DEG in the sequencing data. In line with the Cox regression analysis results, KM curve analysis also (Figure 7) showed that two DELs (FAM182B and LINC00346), four DEMs (hsa-miR-30a-5p, hsa-miR-125b-5p, hsa-miR-10a-5p, and hsa-miR-133a-3p), and seven DEGs (*CDC6, CCNE1, CDK1, E2F2, BUB1, CCNB1,* and *SFN*) were significantly associated with OS but not PRNT (expression value =0 in TCGA data), DSCR4 (P=0.493), and hsa-miR-199a-5p (P=0.101). Also, all the relationships between their expressions and the prognosis results were in line with our expectation, that is, patients with the high expression of the DELs and DEGs (all were upregulated genes in HBV-related HCC) had the poor survival, while patients with the high expression of DEMs (all were downregulated genes in HBV-related HCC) possessed excellent survival. As shown in Figure 8, KM curve analysis also showed that the highly expressed five DEGs (*CDC6, CDK1, BUB1, CCNB1, and SFN*) were significantly associated with RFS.

Further combination with their interaction relationships in the ceRNA network suggested that FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1* ceRNA axes were especially important for the development and prognosis of HBV-related HCC.

Validation of expressions of crucial DELs, DEMs, and DEGs in ceRNA network

The upregulation of LINC00346, *CDK1*, and *CCNE1* but the downregulation of miR-10a-5p and miR-125b-5p was also validated in other microarray datasets and TCGA data.

Category	Term	FDR	Genes
Up	hsa04110:cell cycle	2.16E–08	E2F1, E2F2, CDK1, CDC6, PKMYT1, TTK, CDC20, PTTG1, SFN, CDC25C, CDC25A, CCNB1, CCNE1, CDC45, CCNB2, BUB1, BUB1B
	hsa04080:neuroactive ligand–receptor interaction	2.66E-04	GABRD, CGA, GABRG2, GABRA2, GABRA3, GLRA2, LEP, GRM4, SSTR5, KISSTR, HTRTB, GABRRT, GRID2, NPFFR2, TAART,
			HTRID, GLPIR
	hsa04115:p53 signaling pathway	2.08E-02	CCNBI, CDKI, CCNEI, CCNB2, SFN, GTSEI
	hsa04060:cytokine-cytokine receptor interaction	2.69E-02	LEP, CCR8, CCL20, GDF5, EGF, BMP7, CCL7, IL11, CCL26
	hsa04062:chemokine signaling pathway	2.73E-02	CCR8, GNGT1, CCL20, GNG13, GNG4, CCL7, CCL26
	hsa00604:glycosphingolipid biosynthesis	2.99E-02	ST6GALNAC5, B4GALNT1
	hsa04512:ECM-receptor interaction	3.14E-02	IBSP, COMP, COL2AI, COLIIAI
	hsa04350:TGF-beta signaling pathway	3.33E-02	COMP, GDF5, BMP7, PITX2
	hsa03320:PPAR signaling pathway	4.83E-02	LPL, MMPI, FABP6
Down	hsa00830:retinol metabolism	8.15E-10	CYP3A4, CYPIAI, CYP2B6, CYP2C8, ADHIB, CYP26AI, ADH7,
			CYP1A2, CYP3A43, CYP2A13, CYP4A11, UGT2B17, CYP4A22,
			LRAT, ADH4, CYP2A6, CYP2A7, RDH16
	hsa00982:drug metabolism	2.89E-05	CYP3A4, CYP2B6, CYP2C8, ADH1B, ADH7, CYP1A2, CYP2E1,
			GSTM5, CYP3A43, CYP2A13, UGT2B17, ADH4, CYP2A6, CYP2A7
	hsa04080:neuroactive ligand–receptor	1.79E–04	GPR83, DRD1, GABRB3, DRD5, PTH1R, PRSS1, VIPR1, VIPR2,
	interaction		GCGR, GRIN2B, CNR2, GLP2R, GABRP, NPBWR1, GABRA5,
			NPY I R, NTSR I, NPY 5R, GRIA I, CHRM2, GRM7, PTGDR,
			TBXA2R, AVPRIA, ADRAIA, CTSG, HTR2A
	hsa04060:cytokine–cytokine receptor	2.07E-04	CXCRI, CNTFR, PF4, PF4VI, CCL24, CXCR5, CCL2I, IFNG,
	interaction		XCR1, AMHR2, IL6, IL5, FLT3, TNFRSF13B, TNFRSF13C, IL26,
			CCL19, IL22, CCL17, CCR9, TSLP, CXCL14, PPBP, CD40LG,
			IL5RA, NGFR, IL2
	hsa00980:metabolism of xenobiotics by	3.64E-04	CYP3A43, CYP3A4, UGT2B17, CYP1A1, CYP2B6, ADH4,
	CYP/CYP450		CYP2C8, ADH1B, ADH7, CYP2E1, CYP1A2, GSTM5
	hsa00232:caffeine metabolism	1.50E-03	CYP2A13, NAT2, CYP2A6, CYP2A7, CYP1A2
	hsa00983:drug metabolism	2.10E-02	CYP3A43, CYP3A4, CYP2A13, UGT2B17, NAT2, UPP2, CYP2A6, CYP2A7
	hsa04340:Hedgehog signaling pathway	2.00E-02	WNT2, WNT1, WNT10A, WNT7B, WNT9A, HHIP, GAS1, WNT7A, BMP5

Table 3 KEGG pathway enrichment for differentially expressed genes using the DAVID database

Abbreviations: DAVID, Database for Annotation, Visualization and Integrated Discovery; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.

FAM182B was not found to be differentially expressed in GSE27462 and TCGA data. *E2F2* was demonstrated to be differentially expressed in GSE94660, GSE25599, and TCGA data but not in GSE121248 (Table 8). These findings indicated that LINC00346-miR-10a-5p-*CDK1* ceRNA axis may be a potentially verifiable mechanism for HBV-related HCC.

Discussion

In the present study, we identified FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1* ceRNA axes as important mechanisms for the development of HBV-related HCC. They were involved in HBV-related HCC by influencing cell cycle. Also, the genes in these two axes were significantly associated with the OS of patients. LINC00346-miR-10a-5p-*CDK1* may be especially crucial because *CDK1* was considered as a hub gene in the PPI network and was also associated with RFS as well as the expressions of all of them confirmed in other datasets.

Numerous studies have shown that HBV infection of hepatocytes promotes cell cycle progression by accelerating G1/S and G2/M transition and thus increases cell proliferation ability, ultimately inducing the development of HCC.^{35,36} It is well accepted that CCNE1 is a positive regulator of G1/S phase transition³⁷ and CCNB1 is required for G2/M transition and mitosis resumption by forming a maturation promoting factor with CKD1.³⁸ Transcriptional factor E2F2 can be activated by Cyclin-CDK enzymatic complex after phosphorylating the protein retinoblastoma (Rb), which promotes the transcription of E2F2 Α

в




Figure 2 Function enrichment analyses for the differentially expressed genes. Note: (A) GO enrichment and (B) KEGG pathways enrichment.

Abbreviations: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

target genes to regulate the G1/S-phase transition.³⁹ Thus, CCNE1, CCNB1, CKD1, and E2F2 genes are suggested to be upregulated in HBV-related HCC. These hypotheses have been demonstrated by previous studies. For example, Sung et al⁴⁰ used the RNA sequencing (RNA-seq) and Sanger sequencing to confirm that CCNE1 gene was highly expressed in HBV integrated tumors compared with adjacent normal tissue. Chin et al41 observed that delivery of a replication competent HBV genome into hepatocyte lines Huh7 and PMH induced the expression of CCNB1.




Figure 3 Protein and protein interaction network for the differentially expressed genes. Notes: Red, upregulated; green, downregulated. The larger size of node (protein) indicates the higher degree (interaction relationships) of it. Abbreviation: FC, fold change.

Gene	Degree	Gene	сс	Gene	BC	Gene	APL	Overlapped	Expression
GNGTI	87	IL6	0.3179	IL6	0.2515	IL6	3.1461	CCNBI	Up
GNG13	85	CHRM2	0.2989	UBE2C	0.1845	CHRM2	3.3455	CDKI	Up
GNG4	64	SH3GL2	0.2959	NGF	0.1695	SH3GL2	3.3792	GNG4	Up
CDKI	56	EGF	0.2947	ТН	0.1586	EGF	3.3933	UBE2C	Up
CCNBI	52	ESRI	0.2890	GNGTI	0.1413	ESRI	3.4607	GNGTI	Up
CDC20	48	CCL20	0.2848	FOSB	0.1406	CCL20	3.5112	KIF4A	Up
BUBI	48	GNGTI	0.2846	MMPI	0.1388	GNGTI	3.5140	PF4	Down
CCNB2	47	GNG13	0.2823	CHRM2	0.1186	GNG13	3.5421	GNG13	Up
KIF2C	47	INS	0.2821	SH3GL2	0.1164	INS	3.5449		
РМСН	45	UBE2C	0.2808	EGF	0.1106	UBE2C	3.5618		
AURKB	44	PF4	0.2803	E2F1	0.1043	PF4	3.5674		
CENPA	43	PTHLH	0.2786	ESRI	0.1013	PTHLH	3.5899		
KIF20A	39	GNG4	0.2777	GNG13	0.0956	GNG4	3.6011		
BUBIB	39	NGF	0.2766	INS	0.0904	NGF	3.6152		
NCAPG	38	GNAO I	0.2728	KIF4A	0.0670	GNAOI	3.6657		
CDCA8	38	KIF4A	0.2722	PTHLH	0.0669	KIF4A	3.6742		
GCGR	37	PPBP	0.2713	CDKI	0.0637	PPBP	3.6854		
NPSRI	37	GNA14	0.2709	ACAN	0.0632	GNA14	3.6910		
BIRC5	37	LEP	0.2707	CCL20	0.0620	LEP	3.6938		
TTK	37	TERT	0.2707	GNAO I	0.0593	TERT	3.6938		
NDC80	37	GNAZ	0.2669	CAMK2B	0.0547	GNAZ	3.7472		
DLGAP5	36	NGFR	0.2661	LPL	0.0444	NGFR	3.7584		
UBE2C	35	SYT9	0.2655	CYP19A1	0.0430	SYT9	3.7669		
CDC45	35	E2F1	0.2651	CCNBI	0.0417	E2F1	3.7725		
PF4	34	HTRIB	0.2645	GNG4	0.0402	HTRIB	3.7809		
KIF4A	34	CDKI	0.2639	CHRNAI	0.0394	CDKI	3.7893		
РВК	34	РМСН	0.2639	PF4	0.0393	РМСН	3.7893		
KIF23	34	HTRID	0.2639	RHO	0.0370	HTRID	3.7893		
CXCRI	33	CCNBI	0.2625	NOSI	0.0353	CCNBI	3.8090		
XCRI	33	CXCRI	0.2597	NGFR	0.0348	CXCRI	3.8511		

Table 4 Topological features for each protein in PPI network

Note: Top 30 genes were listed.

Abbreviations: APL, average path length; BC, betweenness centrality; CC, closeness centrality; PPI, protein–protein interaction.




Figure 4 Modules extracted from the protein and protein interaction network. **Notes: (A)** module 1; **(B)** module 2; **(C)** module 3; and **(D)** module 4. Red, upregulated; green, downregulated. The larger size of node (protein) indicates the higher degree (interaction relationships) of it.

Cheng et al⁴² also used in vitro experiments to prove HBV persistently activated the CCNB1-CDK1 kinase in HCC cells. In line with these studies, our study also found CCNE1, CCNB1, and CKD1 were upregulated in tumor samples of patients with HBV-related HCC and the high expression of them predicted poor prognosis. The CKD1 may be especially important because it was associated with both OS and RFS. Although there was a study to indicate E2F2 upregulation in HCC,43 its relationship with HBV has not been investigated. Our study may be the first to reveal that HBV infection may trigger E2F2 upregulation and lead to the development of HCC and poor prognosis for patients. miRNAs are the class of small RNAs (18-25 nucleotides) that downregulate target gene expressions via binding to the 3'-untranslated region (UTR). Thus, the upregulation of cell cycle-related genes may be attributed to the downregulation of miRNAs. In this study, we also investigated the DEMs between tumor and normal samples and predicted their interaction with target genes by the

Module	Description	FDR	Genes in test set
MI	Mitotic cell cycle	9.74E-37	CDCA5 BUB1B CDCA8 NCAPG TTK CENPA SKA1 AUR
			KBJCDC20JCCNB2JCCNB1JPTTG1JNUF2JPBKJNEK2JBU
			BI CEP55 DLGAP5 UBE2C KIF23 NDC80 ANLN KIF18
			A CDK1 BIRC5 KIF2C SPC24 CDKN3 SPC25
	Nuclear division	9.74E-37	CDCA5 BUB1B CDCA8 NCAPG SKA1 AURKB CDC20 C
			CNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP55 D
			LGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1 BIRC
			5 KIF2C SPC24 SPC25
	Mitosis	9.74E-37	CDCA5 BUB1B CDCA8 NCAPG SKA1 AURKB CDC20 C
			CNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP55 D
			LGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1 BIRC
			5 KIF2C SPC24 SPC25
	M phase of mitotic cell cycle	1.65E–36	CDCA5 BUB1B CDCA8 NCAPG SKA1 AURKB CDC20 C
			CNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP55 D
			LGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1 BIRC
			5 KIF2C SPC24 SPC25
	Organelle fission	1.65E–36	CDCA5 BUB1B CDCA8 NCAPG SKA1 AURKB CDC20 C
			CNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP55 D
			LGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1 BIRC
			5 KIF2C SPC24 SPC25
	M phase	2.75E-36	CDCA5 BUB1B CDCA8 NCAPG TTK SKA1 AURKB CDC
			20 CCNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP
			55 DLGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1
			BIRC5 KIF2C TRIP13 SPC24 SPC25

Table 5 BinGO enrichment for genes in modules

(Continued)

Table 5 (Continued)

Module	Description	FDR	Genes in test set
	Cell cycle phase	1.03E-35	CDCA5 BUB1B CDCA8 NCAPG TTK SKA1 AURKB CDC
			20 CCNB2 CCNB1 PTTG1 NUF2 PBK NEK2 BUB1 CEP
			55 DLGAP5 UBE2C KIF23 NDC80 ANLN KIF18A CDK1
			BIRC5 KIF2C TRIP13 SPC24 CDKN3 SPC25
	Cell cycle process	5.27E-34	CDCA5 BUB1B CDCA8 NCAPG TTK CENPA SK
			A I JAURKBJCDC20 JCCNB2 JCCNB I JPTTG I JNUF
			2 PBK NEK2 BUB1 CEP55 DLGAP5 UBE2C KIF
			23 NDC80 ANLN KIF I 8A CDK I BIRC5 KIF2C
			TRIP13 SPC24 CDKN3 SPC25
	Cell cycle	7.78E-34	CDCA5 HJURP BUB1B CDCA8 NCAPG TTK CENPA SK
			A I AURKB CDC20 CCNB2 CCNB1 CDC45 PTTG1 NU
			F2 PBK NEK2 BUB CEP55 DLGAP5 UBE2C KIF23 ND
			C80 ANLN KIF18A CDK1 BIRC5 KIF2C TRIP13 SPC24
			CDKN3 SPC25
	Cell division	8.53E-28	
	Cell division	0.535-20	UBE2CICDCA5 BUB1B CDCA8 NCAPG KIF23 SKA1 A
			URKBINDC80 CDC20 CCNB2 ANLN CCNB1 PTTG1
			NUF2 CDK1 BIRC5 NEK2 KIF2C BUB1 CEP55 SPC24
			SPC25
M2	G-protein-coupled receptor protein	4.81E-36	NPFFR2 CHRM2 PMCH CXCR5 HTR2A ADRA1A GNGT
	signaling pathway		I GNA I 4 GRM4 CXCR I CNR2 TBXA2R NPBWR I KISS
			IR CCR9 CCR8 PROK2 TAC3 NTSR1 P2RY12 XCR1 ED
			N2 NPY5R GCGR HTR1D NPY1R HTR1B CCK AVPR1A
			SSTR5 GNG13 PPYR1 PNOC
	Cell surface receptor-linked signaling	8.03E-26	NPFFR2 CHRM2 PMCH CXCR5 HTR2A ADRA1A GNGT
	pathway		I GNA I 4 GRM4 CXCR I CNR2 TBXA2R NPBWR I KISS
			IR CCR9 CCR8 PROK2 TAC3 NTSR1 P2RY12 XCR1 ED
			N2 NPY5R EDN3 GCGR HTR1D NPY1R HTR1B CCK A
			VPR1A SSTR5 GNG13 PPYR1 PNOC PF4
	Signaling	6.64E-24	NPFFR2 CHRM2 PMCH CXCR5 OXT HTR2A ADRA1A
			GNGT1 GNA14 GRM4 CXCR1 CNR2 GRM7 TBXA2R
			GNG4 NPBWR1 KISS1R CCR9 CCR8 PROK2 TAC3 CCL
			19 NTSR1 P2RY12 XCR1 EDN2 NPY5R CCL21 EDN3
			CCL20 GCGR HTRID NPYIR HTRIB CCK AVPRIA SST
			R5 GNG13 APLN PPYR1 PNOC GNRH2 PF4
	Behavior	1.44E-23	PMCH OXT HTR2A GRM4 CXCR1 CNR2 KISS1R CCR
			9 CCR8 PROK2 CCL19 NTSR1 XCR1 EDN2 NPY5R C
			CL21 EDN3 CCL20 NPY1R HTR1B CCK AVPR1A PPBP
			IPPYR1 IPF4
	Signaling pathway	3.33E-20	NPFFR2 CHRM2 PMCH CXCR5 HTR2A ADRA1A GNGT
	Signaling pacitway	5.552-20	I GNA I 4 GRM4 CXCR I CNR2 TBXA2R GNG4 NPBW
			R I KISS I R I CCR9 CCR8 PROK2 TAC3 NTSR I P2RY I 2 X
			CRI JEDN2 NPY5R JEDN3 JGCGR HTRI D NPY I R HTRI B
	C . 1 .	2045 17	CCK AVPRIALSSTR5 GNG I 3 PPYR I PNOC PF4
	Signaling process	2.04E-17	CHRM2 PMCH OXT HTR2A ADRAIA GNGTI GNAI4
			GRM4 CNR2 GRM7 NPBWR1 KISS1R PROK2 CCL19 N
			TSR1 P2RY12 XCR1 EDN2 NPY5R CCL21 EDN3 CCL2
			0 GCGR HTR1D NPY1R HTR1B CCK AVPR1A SSTR5 G
			NG13 APLN PNOC GNRH2 PF4

(Continued)

 Table 5 (Continued)

Module	Description	FDR	Genes in test set
	Signal transmission	2.04E-17	CHRM2 PMCH OXT HTR2A ADRA1A GNGT1 GNA14
			GRM4 CNR2 GRM7 NPBWR1 KISS1R PROK2 CCL19 N
			TSR1 P2RY12 XCR1 EDN2 NPY5R CCL21 EDN3 CCL2
			0 GCGR HTR D NPY R HTR B CCK AVPR A SSTR5 G
			NG I 3 APLN PNOC GNRH2 PF4
	Signal transduction	1.43E–14	CHRM2 PMCH OXT HTR2A ADRA1A GNGT1 GNA14
			GRM4 CNR2 KISS1R PROK2 CCL19 P2RY12 XCR1 ED
			N2 CCL21 EDN3 CCL20 GCGR HTR1D NPY1R HTR1B
			CCK AVPR1A SSTR5 GNG13 APLN PNOC GNRH2 PF4
	Response to stimulus	2.05E-12	NPFFR2 CHRM2 PMCH OXT HTR2A ADRA1A GNGT1
			GRM4 CXCR1 CNR2 GRM7 GNG4 KISS1R CCR9 CCR8
			PROK2 CCL19 NTSR1 P2RY12 XCR1 EDN2 NPY5R C
			CL21 EDN3 CCL20 GCGR HTR1D NPY1R HTR1B CCK
			AVPR I A PPBP GNG I 3 APLN PPYR I PF4
	Response to chemical stimulus	2.96E-11	XCR1 EDN2 CCL21 EDN3 CCL20 GCGR HTR1D NP
			YIR HTRIB OXT CCK HTR2A AVPRIA PPBP ADRAIA
			GNG13 CXCR1 CNR2 GNG4 CCR9 CCR8 PROK2 CC
			L19 PF4
M3	Cyclic-nucleotide-mediated signaling	6.43E-09	GLP I R VIPR I GLP2R PTH I R DRD I PTHLH DRD 5
	G-protein-coupled receptor protein	2.93E-08	VIPR I GPR I 5 GLP2R PTH I R DRD I TAAR I PTHLH DR
	signaling pathway		D5 PTGDR
	Second messenger-mediated signaling	9.78E-08	GLP I R VIPR I GLP2R PTH I R DRD I PTHLH DRD5
	G-protein signaling, coupled to cyclic	9.78E-08	VIPR I GLP2R PTH I R DRD I PTHLH DRD5
	nucleotide second messenger	7.702 00	
	Cell surface receptor-linked signaling	2.27E-05	VIPR I GPR I 5 GLP2R PTH I R DRD I TAAR I PTHLH DR
	pathway	2.27 L=05	D5 PTGDR
	Signaling	3.01E-05	GLP I R VIPR I GPR I 5 VIPR2 GLP2R PTH I R DRD I CGA T
	Signaling	5.012-05	AAR I IPTHLHIDRD5 IPTGDR
	Signaling pathway	5.37E-05	GLP I R VIPR I GPR I 5 GLP2R PTH I R DRD I TAAR I PTH
		3.37E-03	LHIDRD5 PTGDR
	Intracellular signal transduction	8.25E-05	GLP I R VIPR I GLP2R PTH I R DRD I PTHLH DRD5
	Cell–cell signaling	1.41E-04	VIPR1 VIPR2 DRD1 CGA PTHLH DRD5
		1.59E-04	GLP I R VIPR I VIPR2 GLP2R PTH I R DRD I CGA PTHLH
	Signal transduction	1.37E-04	
	Circulia		
	Signaling process	4.51E-04	GLP I R VIPR I VIPR2 GLP2R PTH I R DRD I CGA PTHLH
		7.05.04	
	Cell communication	7.10E-04	VIPR I VIPR2 DRD I CGA PTHLH DRD 5
M4	Drug metabolic process	3.44E–16	CYP2A6 CYP2C8 CYP2B6 CYP1A2 CYP1A1 CYP2E1 C YP3A4
	Secondary metabolic process	4.89E–11	CYP26A1 CYP2A6 CYP1A2 CYP1A1 CYP2E1 CYP3A4
	Oxidation reduction	2.91E-10	CYP26A1/CYP2A6/CYP2C8/CYP2B6/CYP4A11/CYP1A2/C
	Oxidation reduction	2.712-10	YPIA1 CYP2E1 CYP3A4
	Steroid metabolic process	4.045 10	
	steroid metabolic process	4.84E-10	CYP2A6 CYP2B6 CYP1A2 CYP1A1 UGT2B17 CYP2E1
	Lipid metabolic process	1.79E–09	CYP26A1 CYP2A6 CYP2B6 CYP4A11 CYP1A2 CYP1A1
	Bosponso to drug		
	Response to drug	1.12E-07	CYP2A6 CYP2C8 CYP2B6 CYP1A2 CYP1A1 CYP3A4
	Cellular catabolic process	2.17E-06	CYP26A1 CYP2A6 CYP2C8 CYP2B6 CYP1A2 CYP1A1 CYP3A4
	Small malagula metabolis and	3 795 04	
	Small molecule metabolic process	3.78E–06	CYP26A1 CYP2A6 CYP2C8 CYP2B6 CYP4A11 CYP1A2
			CYPIAI CYP3A4
		4 075 04	
	Cellular lipid metabolic process Catabolic process	6.87E–06 9.30E–06	CYP26A1 CYP4A11 CYP1A2 CYP1A1 CYP2E1 CYP3A4 CYP26A1 CYP2A6 CYP2C8 CYP2B6 CYP1A2 CYP1A1

Abbreviation: FDR, false discovery rate.




Figure 5 ceRNAs interaction network of IncRNA-miRNA-mRNA.

Notes: Square nodes represent lncRNAs; triangle nodes represent miRNAs; circular nodes represent mRNAs. Red, upregulated; green, downregulated. Abbreviation: FC, fold change.

Term	P-value	Genes
hsa04110:cell cycle	2.85E-06	CCNBI, E2F2, CDKI,
		CCNEI, CDC6, BUBI, SFN
hsa04115:p53	0.001617	CCNBI, CDKI, CCNEI, SFN
signaling pathway		
hsa04080:neuroactive	0.04606	GPR83, GABRB3
ligand–receptor		
interaction		
hsa05200:pathways in	0.046995	E2F2, CCNE1
cancer		

 Table 6 KEGG pathways for genes in ceRNA network

Abbreviation: KEGG, Kyoto Encyclopedia of Genes and Genomes.

miRwalk database. Our results indicated that miR-10a-5p and miR-125b-5p could regulate *CDK1/CCNE1* and *E2F2*, respectively. There have studies to explore the miRNAs to regulate these target genes in HCC, such as miR-7/497/195-*CCNE1*,^{44,45} miR-582-5p-*CDK1*,⁴⁶ and miR-214/490-*E2F2*,^{47,48} but not focused on the relationships of our prediction. However, the studies on the expressions of miR-10a-5p and miR-125b-5p in HCC may indirectly

illuminate their underlying negative relations. Zhu et al49 identified the DEMs in seven paired specimens of HCC using the microarray technique and found that miR-10a-5p and miR-125b-5p were significantly downregulated. Overexpression of miR-10a50 and miR-125b51 was reported to suppress the metastasis of HCC cells in vivo. In line with these studies, our study also showed that miR-10a-5p and miR-125b-5p were downregulated in HBV-related HCC and high expression of them predicted excellent prognosis. lncRNAs are proposed to act as a ceRNA to involve in the regulation effects of miRNAs on the expression of target genes. Thus, the upregulation of cell cycle-related genes may also be attributed to the upregulation of lncRNAs that sponged the miRNAs. In this study, we also investigated the DELs between tumor and normal samples and predicted their interaction with miRNAs by the miRcode database. Our results indicated that upregulated FAM182B and LINC00346 may regulate cell cycle-related genes by interacting with miR-125b-5p and miR-10a-5p, resulting in poor prognosis. In line with our study, there has been a study to demonstrate that LINC00346 was upregulated




Figure 6 HCC-related ceRNAs interaction network of IncRNA-miRNA-mRNA.

Notes: Square nodes represent circRNAs, triangle nodes represent miRNAs, circular nodes represent mRNAs, and rhombus nodes represent HCC pathways. Red, upregulated; green, downregulated.

Abbreviations: FC, fold change; HCC, hepatocellular carcinoma.

Table 7 Cox regression and	lysis to screen	survival-re	elated genes
----------------------------	-----------------	-------------	--------------

ID	Overall s	urvival	Recurren	ce-
			free survival	
	HR	P-value	HR	P-value
E2F2	1.24	0.049	1.19	0.16
CDC6	1.28	0.0372	1.41	0.0099
CCNEI	1.05	0.0456	1.08	0.32
CDKI	1.32	0.022	1.48	0.0036
BUBI	1.31	0.013	1.37	0.0054
CCNBI	1.4	0.014	1.36	0.023
SFN	1.22	0.0023	1.19	0.0055
hsa-miR-10a-5p	0.882	0.04	0.854	0.27
hsa-miR-125b-5p	0.835	0.019	0.952	0.74
hsa-miR-133a-3p	0.11	0.045	0.879	0.39
hsa-miR-199a-5p	0.986	0.88	0.907	0.28
hsa-miR-30a-5p	0.911	0.0452	0.866	0.32
LINC00346	1.67	0.0051	0.99	0.85
DSCR4	1.03	0.68	0.994	0.95
FAM182B	1.152	0.047	0.84	0.19

in bladder cancer tissues compared to normal tissues. Knockdown of LINC00346 inhibited bladder cancer cell proliferation and migration and induced cell cycle arrest and cell apoptosis.⁵² The high expression of LINC00346 was also found to be significantly associated with poor OS in HCC⁵³ and breast cancer samples.⁵⁴ Nevertheless, no studies were performed to investigate the interaction of LINC00346 with miRNAs. Also, any investigation related to FAM182B has not been found until now. These implied that our identified ceRNA axes (FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1*) may be novel mechanisms for HBV-related HCC.

There were some limitations in this study. First, our study has preliminarily predicted that these ceRNA axes may be associated with the development of HBV-related HCC and some of them were confirmed in some other microarray datasets. Thus, further clinical, in vitro (dual luciferase reporter assay), and in vivo (loss of function) experiments are necessary to validate the expressions of controversial genes (such as FAM182B and E2F2) and regulatory relationships between DELs and DEMs as well as between DEMs and DEGs, and their roles for the proliferation, metastasis, and invasion of HBV infection hepatocytes. Second, there were no clinical data in our used datasets (GSE77509 and GSE76903) and, thus, we only preliminarily predicted the associations between prognosis (OS and RFS) and each of our identified DEL/DEM/DEG using TCGA data via univariate cox regression analysis. Whether these genes were independent biomarkers needed further clinical trials with multivariate Cox's model that integrated all the clinical information (such as HBV DNA level, liver function parameters, pathologic stage, pathologic node, and pathologic metastasis, grade, therapeutic strategies including hepatectomy, radiofrequency ablation, and solafenib)55-57 and all DELs/DEMs/DEGs expression levels.




Figure 7 Kaplan–Meier analysis to display the correlation of differentially expressed lncRNAs (A), miRNAs (B), and genes (C) with overall survival outcomes for patients with HBV-related HCC.


Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

Conclusion


The present study preliminarily indicates that FAM182B and LINC00346 may be novel prognostic biomarkers and therapeutic targets for HBV-associated HCC. They function as a ceRNA to sponge miR-125b-5p and miR-10a-5p to derepress cell cycle-related genes (*E2F2, CDK1,* and *CCNE1*) and promote the cell growth of HCC cells.

Ethics approval and informed consent


As the data used in this study were downloaded from GEO or TCGA database, and no human experiment was involved in this study, there were no ethical approval and informed consent. Thus, the principles of the Declaration of Helsinki were also not followed.




BUB1



CCNB1





SFN




Figure 8 Kaplan–Meier analysis to display the correlation of differentially expressed genes with recurrence-free survival outcomes for patients with HBV-related HCC. Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

894 submit your manuscript | www.dovepress.com Dovepress

RNA type	Dataset	Symbol	Tumor (mean ± SD)	Control (mean ± SD)	P-value
IncRNA	GSE27462	FAM182B	75.834±27.913	71.793±23.127	0.8096
		LINC00346	124.665±28.955	72.848±14.226	0.01208
	TCGA	FAM182B	3.403±1.255	2.539±0.944	0.081
		LINC00346	14.834±3.436	12.679±1.403	0.0397
miRNA	GSE69580	miR-125b-5p	39.384±23.416	355.428±82.423	0.000606
		miR-10a-5p	4.229±2.103	10.111±2.647	0.00507
	TCGA	miR-125b-5p	8.962±1.092	10.203±0.352	4.09E-08
		miR-10a-5p	13.607±1.198	14.779±0.472	4.89E-06
mRNA	GSE121248	E2F2	4.252±0.181	4.239±0.157	0.696
		CDKI	7.224±1.105	5.379±0.799	2.68793E-16
		CCNEI	7.056±1.032	6.415±0.216	0.00000344
	GSE94660	E2F2	0.83±0.443	0.0611±0.028	I.234E-07
		CDKI	2.141±0.769	0.251±0.121	2.9E-10
		CCNEI	1.412±0.669	0.242±0.129	9.01E-08
	GSE25599	E2F2	0.769±0.496	0.302±0.255	0.01958
		CDKI	5.116±2.925	1.152±0.923	0.005978
		CCNEI	2.015±1.820	0.430±0.242	0.02254
	TCGA	E2F2	5.612±1.296	2.959±1.076	0.000926
		CDKI	8.018±1.428	4.579±1.266	0.00374
		CCNEI	6.322±1.993	3.162±0.979	0.00193

Table 8 Confirmation of expressions of crucial IncRNAs, miRNAs, and mRNAs using other datasets

Abbreviation: TCGA, The Cancer Genome Atlas.

Availability of data and materials

All the microarray data were downloaded from the GEO database in NCBI (<u>http://www.ncbi.nlm.nih.gov/geo/</u>). The mRNA and miRNA Seq-data were obtained from TCGA (<u>https://tcga-data.nci.nih.gov/</u>).

Author contributions

HL and ZB participated in the conception and design of this study. HL and XZ performed the acquisition of data. CL and CS were involved in the analysis and interpretation of data. HL and CL performed the statistical and bioinformatics analyses. HL drafted the manuscript. ZB revised the manuscript for important intellectual content. All authors read and approved the final manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin.* 2016;66(2):115–132.
- Li J, Huang L, Yan J, Qiu M, Yan Y. Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. ANZ J Surg. 2018;88(10):E713–E717.
- Li Y, Zhang Z, Shi J, et al. Risk factors for naturally-occurring earlyonset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. *Int J Clin Exp Med.* 2015;8(1):1205–1212.

- Xiang L, Liu K, Chen Y. Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis. *Int J Environ Res Public Health*. 2016;13(6):604.
- Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(1):10–17.
- Fan H, Zhang Q, Zhao X, Lv P, Liu M, Tang H. Transcriptomic profiling of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. *Oncotarget*. 2017;8(39):65421–65434.
- Mou Y, Wang D, Xing R, et al. Identification of long noncoding RNAs biomarkers in patients with hepatitis B virus-associated hepatocellular carcinoma. *Cancer Biomark*. 2018;23(1):95–106.
- Zuo K, Kong L, Xue D, Yang Y, Xie L. The expression and role of lncRNA AX800134 in hepatitis B virus-related hepatocellular carcinoma. *Virus Genes*. 2018;54(4):475–483.
- Lv D, Wang Y, Zhang Y, Cui P, Xu Y. Downregulated long non-coding RNA DREH promotes cell proliferation in hepatitis B virus-associated hepatocellular carcinoma. *Oncol Lett.* 2017;14(2):2025–2032.
- Yang F, Zhang L, Huo X-Song, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. *Hepatology*. 2011;54(5):1679–1689.
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell*. 2011;146(3):353–358.
- Li Y, Liu G, Li X, Dong H, Xiao W, Lu S. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway. *Biochem Biophys Res Commun.* 2018;503(4):2826–2832.
- Sui J, Yang X, Qi W, et al. Long Non-Coding RNA Linc-USP16 Functions As a Tumour Suppressor in Hepatocellular Carcinoma by Regulating PTEN Expression. *Cell Physiol Biochem*. 2017;44(3):1188–1198.
- 14. Lv J, Fan HX, Zhao XP, et al. Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. *Cancer Lett.* 2016;382(2):166–175.
- Mo Y, He L, Lai Z, et al. LINC01287/miR-298/STAT3 feedback loop regulates growth and the epithelial-to-mesenchymal transition phenotype in hepatocellular carcinoma cells. *J Exp Clin Cancer Res.* 2018;37(1):149.

- Fan H, Lv P, Mu T, et al. LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells. *Cancer Lett.* 2018;429:89–99.
- Lan T, Ma W, Hong Z, Wu L, Chen X, Yuan Y. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. *J Exp Clin Cancer Res.* 2017;36(1):11.
- Xie CR, Wang F, Zhang S, et al. Long Noncoding RNA HCAL Facilitates the Growth and Metastasis of Hepatocellular Carcinoma by Acting as a ceRNA of LAPTM4B. *Mol Ther Nucleic Acids*. 2017;9:440–451.
- Yang Y, Chen L, Gu J, et al. Recurrently deregulated lncRNAs in hepatocellular carcinoma. *Nat Commun.* 2017;8:14421.
- Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H. The HUGO Gene Nomenclature Committee (HGNC). *Human Genetics*. 2001;109(6):678–680.
- Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. *Methods Mol Biol.* 2014;1150:45–79.
- 22. Pollard KS, Dudoit S, Laan MJ. Multiple testing procedures: the multtest package and applications to genomics. In: Gentleman R., Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*. New York: Springer; 2005:249–271.
- Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: proteinprotein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* 2015;43(D1):D447–D452.
- Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. *Methods Mol Biol.* 2011;696:291–303.
- Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. *Biosystems*. 2015;127:67–72.
- Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics*. 2003;4(1):2.
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc.* 2009;4(1):44–57.
- Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. *Bioinformatics*. 2005;21(16):3448–3449.
- Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. *Bioinformatics*. 2012;28(15):2062–2063.
- Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNAtarget interactions. *Nat Methods*. 2015;12(8):697.
- Davis AP, Grondin CJ, Johnson RJ, Sciaky D, et al. The Comparative Toxicogenomics Database: update 2017. *Nucleic Acids Res.* 2017;45(D1):D972–D978.
- 32. Yoo S, Wang W, Wang Q, et al. A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis. *BMC Med.* 2017;15(1):214.
- Huang Q, Lin B, Liu H, et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. *PLoS One*. 2011;6(10):e26168.
- 34. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. *Hepatology*. 2011;54(5): 1679–1689.
- Zheng BY, Gao WY, Huang XY, et al. HBx promotes the proliferative ability of HL-7702 cells via the COX-2/Wnt/β-catenin pathway. *Mol Med Rep.* 2018;17(6):8432–8438.
- Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ. Hepatitis B virus deregulates cell cycle to promote viral replication and a premalignant phenotype. *J Virol*. 2018;92(19)):e00722–18pii:.

- Luo Q, Li X, Li J, et al. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. *Int J Oncol.* 2013;43(4): 1212–1218.
- Fang Y, Yu H, Liang X, Xu J, Cai X. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. *Cancer Biol Ther*. 2014;15(9):1268–1279.
- Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. *Oncogene*. 2005;24(17):2810–2826.
- Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. *Nat Genet*. 2012;44(7): 765–769.
- Chin R, Earnest-Silveira L, Koeberlein B, et al. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis. *J Hepatol*. 2007;47(3):325–337.
- Cheng P, Li Y, Yang L, et al. Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. *Oncol Rep.* 2009;22(5):1101–1107.
- Gnani D, Romito I, Artuso S, et al. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. *Cell Death Differ*. 2017;24(5):889–902.
- Furuta M, Kozaki K, Tanimoto K, et al. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. *PLoS One.* 2013;8(3):e60155.
- 45. Zhang X, Hu S, Zhang X, et al. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. *Biochem Biophys Res Commun.* 2014;443(3):1078–1084.
- Zhang Y, Huang W, Ran Yet al. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. *Tumour Biol.* 2015;36(11):8309–8316.
- Wang P, Chen S, Fang H, et al. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators. *Oncotarget*. 2016;7(1):929–945.
- Fang ZQ, Li MC, Zhang YQ, Liu XG. MiR-490-5p inhibits the metastasis of hepatocellular carcinoma by down-regulating E2F2 and ECT2. *J Cell Biochem*. 2018;119(10):8317–8324.
- Zhu HR, Huang RZ, Yu XN, et al. Microarray expression profiling of microRNAs reveals potential biomarkers for hepatocellular carcinoma. *Tohoku J Exp Med.* 2018;245(2):89–98.
- Yan Y, Luo YC, Wan HY, et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. *Hepatology*. 2013;57(2):667–677.
- 51. Zhou HC, Fang JH, Shang LR, et al. MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. *J Pathol.* 2016;240(4):450–460.
- Ye T, Ding W, Wang N, Huang H, Pan Y, Wei A. Long noncoding RNA linc00346 promotes the malignant phenotypes of bladder cancer. *Biochem Biophys Res Commun.* 2017;491(1):79–84.
- Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. *PLoS One*. 2015;10(10):e0141042.
- Liu H, Li J, Koirala P, et al. Long non-coding RNAs as prognostic markers in human breast cancer. *Oncotarget*. 2016;7(15):20584–20596.
- Akuta N, Suzuki F, Kobayashi M, et al. Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance. *J Med Virol.* 2018;90(10):1586–1592.
- Nie QH, Gao LH, Cheng YQ, et al. Hepatitis C virus infection of human cytotrophoblasts cultured in vitro. J Med Virol. 2012;84(10):1586–1592.
- Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J. Activation of PI3K/ AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma. *Cancer Biomark*. 2018;23(1):33–43.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Dovepress